Cited 29 times in
Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김세주 | - |
dc.contributor.author | 석정호 | - |
dc.contributor.author | 이성희 | - |
dc.contributor.author | 이은 | - |
dc.contributor.author | 이홍식 | - |
dc.date.accessioned | 2015-04-23T16:57:02Z | - |
dc.date.available | 2015-04-23T16:57:02Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0302-282X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/101539 | - |
dc.description.abstract | BACKGROUND: Polymorphisms of serotonin transporter, especially serotonin transporter linked promoter region (5- HTTLPR) and serotonin transporter intron 2 variable number tandem repeat (5-HTTVNTR), have been suggested to be associated with treatment response to selective serotonin reuptake inhibitors. However, there have been only few reports of the association between 5-HTTLPR or 5-HTTVNTR and treatment response to venlafaxine. METHODS: 84 Korean major depressive disorder patients were included in this study. They were administered 75 mg of venlafaxine XR (extended release) for 1 week and then took 150 mg for the next 3 weeks. All patients were evaluated at baseline and week 4 by the Hamilton Depression Rating Scale (HAM-D), Montgomery-Asberg Depression Rating Scale (MADRS), Beck Depression Inventory (BDI), Hamilton Anxiety Rating Scale (HAM-A), and Beck Anxiety Inventory (BAI). RESULTS: (1) Treatment response of depressive symptoms (BDI, HAM-D, MADRS) to venlafaxine at week 4 was associated with the non-s/s (l/l and l/s) genotype of 5-HTTLPR; (2) in repeated measures ANOVA, the BDI, MADRS and HAM-A scores decreased more significantly in patients with the non-s/s genotype than in those with the s/s genotype, and (3) multiple regression analyses suggested that the 5-HTTLPR polymorphism is a predictive factor for short-term treatment response to venlafaxine. However, 5-HTTVNTR showed no significant association with treatment response to venlafaxine. Both 5-HTTLPR and 5-HTTVNTR were not associated with side effects of venlafaxine. CONCLUSION: The 5-HTTLPR non-s/s genotype can be associated with venlafaxine treatment responses. However, further large-scale studies are warranted to confirm this finding. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 198~206 | - |
dc.relation.isPartOf | NEUROPSYCHOBIOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Alleles | - |
dc.subject.MESH | Asian Continental Ancestry Group/genetics | - |
dc.subject.MESH | Cyclohexanols/administration & dosage* | - |
dc.subject.MESH | Delayed-Action Preparations/administration & dosage | - |
dc.subject.MESH | Depressive Disorder, Major/drug therapy* | - |
dc.subject.MESH | Depressive Disorder, Major/genetics* | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Polymorphism, Genetic | - |
dc.subject.MESH | Psychiatric Status Rating Scales | - |
dc.subject.MESH | Serotonin Plasma Membrane Transport Proteins/genetics* | - |
dc.subject.MESH | Serotonin Uptake Inhibitors/administration & dosage* | - |
dc.subject.MESH | Venlafaxine Hydrochloride | - |
dc.title | Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pharmacology (약리학) | - |
dc.contributor.googleauthor | Sang-Hyuk Lee | - |
dc.contributor.googleauthor | Tae Kyou Choi | - |
dc.contributor.googleauthor | Eun Lee | - |
dc.contributor.googleauthor | Jeong-Ho Seok | - |
dc.contributor.googleauthor | Sung Hee Lee | - |
dc.contributor.googleauthor | Hong Shick Lee | - |
dc.contributor.googleauthor | Se Joo Kim | - |
dc.identifier.doi | 10.1159/000319362 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00604 | - |
dc.contributor.localId | A01929 | - |
dc.contributor.localId | A02876 | - |
dc.contributor.localId | A03032 | - |
dc.contributor.localId | A03332 | - |
dc.relation.journalcode | J02354 | - |
dc.identifier.eissn | 1423-0224 | - |
dc.identifier.pmid | 20664233 | - |
dc.subject.keyword | 5-HTTLPR polymorphism | - |
dc.subject.keyword | Treatment response | - |
dc.subject.keyword | Venlafaxine | - |
dc.subject.keyword | Genetics | - |
dc.contributor.alternativeName | Kim, Se Joo | - |
dc.contributor.alternativeName | Seok, Jeong Ho | - |
dc.contributor.alternativeName | Lee, Sung Hee | - |
dc.contributor.alternativeName | Lee, Eun | - |
dc.contributor.alternativeName | Lee, Hong Shick | - |
dc.contributor.affiliatedAuthor | Kim, Se Joo | - |
dc.contributor.affiliatedAuthor | Seok, Jeong Ho | - |
dc.contributor.affiliatedAuthor | Lee, Sung Hee | - |
dc.contributor.affiliatedAuthor | Lee, Eun | - |
dc.contributor.affiliatedAuthor | Lee, Hong Shick | - |
dc.citation.volume | 62 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 198 | - |
dc.citation.endPage | 206 | - |
dc.identifier.bibliographicCitation | NEUROPSYCHOBIOLOGY, Vol.62(3) : 198-206, 2010 | - |
dc.identifier.rimsid | 47802 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.